The relatively new drug for Hepatitis C, Sovaldi, has caused a rather large controversy about the appropriate price for medication. This NY Times article is one example of the controversy, citing the cost at $1,000 a pill, and $84,000 for a complete treatment.
I'm not asking about what price is appropriate, this is a much more complicated debate and entirely off-topic here. But I am interested in putting the price in context, and the official statement from Gilead paints a rather different picture than most of the articles in the press I read. They state in their policy position:
Sovaldi was priced such that the total regimen cost is comparable to the previous standard of care regimen for genotype 1 patients with hepatitis C.
Is that statement accurate? Is the cost for a complete treatment with Sovaldi comparable to the cost of the existing treatments for Hepatitis C?